FG001 was well tolerated, and light was detected in all patients at the fifth dose level (16mg) administered in the evening before surgery

FG001 is anticipated to be well tolerated and selection of the dose for use in the part 2 of the trial will therefore be based on optimal illumination of the tumor. The Company has now narrowed it down to one of two dose levels (16mg and 24mg). Consolidated safety data will therefore be communicated in Q3 following conclusion of the now initiated 24mg morning dosing at the day of surgery.

The Company has decided, based on the strong data seen from the completed evening-dose testing, that it will generate additional dose-selection data by testing the selected two doses (16mg and 24 mg) with a morning or evening administration the day before surgery. The optimal dose selection and top-line efficacy from part I is therefore expected in Q1-2022. Efficacy results from the second phase enrolling 12 patients from both Denmark and Sweden are anticipated mid-2022.

Five patients were included at the fifth dose level administered in the evening the day before surgery as one patient turned out to have another cancer type than high-grade glioma. This is not uncommon as it can be difficult to diagnose patients based on the pre-surgery images. Light was also detected in this patient, which underlines the potential of using uPAR targeted fluorescence to guide surgery of multiple types of cancer.

“We are excited about the strong result in the first evening administration” says Morten Albrechtsen, CEO and continues “It is reassuring to see yet another cancer type being illuminated using the uPAR targeted guidance of surgery”.

This disclosure contains information that Fluoguide is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-08-2021 12:26 CET.